Newer psoriasis drugs top the old, but it’s not efficacy that counts. It’s payer negotiations: analyst

With this weekend’s American Academy of Dermatology meeting officially wrapped up, one thing is clear: Psoriasis treatments are getting more effective. But that doesn’t mean patients have easy access to a new-and-improved crop of blockbuster hopefuls.Original Article